Universal Biosensors (UBI) is a
medical diagnostics company focused on the research, development and
manufacture of diagnostic test systems for point-of-care (POC) professional and
home use. The point-of-care diagnostic market is worth US$15 billion a year and
UBI has partnered with global
healthcare company Siemens Healthcare Diagnostics to develop the Xprecia StrideTM blood coagulation analyser, launched in
December 2014, to help patients taking the anticoagulant drug Warfarin manage
UBI has also developed a blood
glucose monitoring product that is being commercialised globally by LifeScan,
Inc. (a Johnson & Johnson company) under the OneTouch® Verio® brand.
UBI's innovative electrochemical
sensor platform is being applied to a range of other medical diagnostic
The company is listed on the
Australian Securities Exchange under the ticker "UBI", and operates
from its manufacturing and R&D facility in Melbourne, Australia.
Read more about Corporate Overview & Strategy